Skip to main
LONA

LeonaBio Inc (LONA) Stock Forecast & Price Target

LeonaBio Inc (LONA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LeonaBio is a clinical-stage biopharmaceutical company with a pipeline of promising drug candidates, including lasofoxifene and ATH-1105, that have the potential to address high unmet medical needs in metastatic breast cancer and ALS. The company's development strategy, including a focus on combination therapies and label expansions, positions it well for success in the competitive oncology market. Additionally, LeonaBio's successful Phase 2 trials and well-funded financials make it an attractive investment opportunity.

Bears say

LeonaBio is currently developing lasofoxifene, a potential treatment for ER+/HER2- metastatic breast cancer (mBC) with potentially differentiated benefits compared to existing standard of care (SOC). However, despite the promising clinical profile and potential best-in-class efficacy, the company may face challenges in penetrating the competitive HER2- mBC market and may also have to navigate potential drug-drug interactions due to its mechanism of action as a selective estrogen receptor modulator (SERM). Additionally, while early data does support the safety and efficacy of lasofoxifene, more data and regulatory approvals are needed before it can be considered a commercially viable therapy.

LeonaBio Inc (LONA) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeonaBio Inc (LONA) Forecast

Analysts have given LeonaBio Inc (LONA) a Buy based on their latest research and market trends.

According to 3 analysts, LeonaBio Inc (LONA) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeonaBio Inc (LONA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.